Navigation Links
EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
Date:10/2/2008

ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has received approval from the Nasdaq Listing Qualifications Department to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer will become effective as of the opening of the market on Friday, October 3, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

The Nasdaq Global Select Market, the Nasdaq Global Market, and the Nasdaq Capital Market are the three market tier designations for companies listed on the Nasdaq. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market. EntreMed's trading symbol will remain "ENMD" and trading of the Company's stock will be unaffected by this change. Securities listed on the Nasdaq Capital Market must meet certain financial requirements and adhere to Nasdaq's corporate governance standards.

The Company's decision to transfer to the Nasdaq Capital Market is in response to a letter dated April 4, 2008 from the Nasdaq Stock Market, LLC notifying the Company that its common stock failed to close above the minimum closing bid price of $1.00 per share for 30 consecutive business days, which is required for listing on the Nasdaq Global Market. Transfer to the Nasdaq Capital Market extends the requirement to achieve a minimum $1.00 bid price until March 30, 2009.

James S. Burns, President and Chief Executive Officer, commented, "We have sufficient capital to advance our
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
7. EntreMed Announces 2008 Corporate and Clinical Program Priorities
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 Space ... Human exploration of space requires astronauts to maintain consistently ... and success, and prevent potential errors and accidents. Despite ... is known about how cognition is affected by prolonged ... Now, Penn Medicine researchers are poised to ...
(Date:11/26/2014)... November 26, 2014 PMG Research, Inc. ... PMG Research is a network of sites that provide clinical ... over 2 million patient lives through its partnerships with large ... of 11 hub site locations in the Southeastern United States ... term of the board will be held by: ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
(Date:11/26/2014)... SoundConnect , an award winning unified communications ... Darren Suders has joined the team as Director of ... partner program through innovative offerings, consistent partner ... brings more than 10-years of channel telecommunication experience to ... from policy development, to partner education and to expansion. ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2
... Silence Therapeutics plc (AIM: SLN), a leading international ... partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant ... worldwide license to develop and commercialise QPI-1002, a p53 ... Quark is currently conducting a Phase II ...
... 19 US Oncology, Inc., the nation,s ... than two decades it has played a role in ... the US Food and Drug Administration (FDA). ... http://www.newscom.com/cgi-bin/prnh/20100517/DA06089LOGO ) Tasigna ® (nilotinib) capsules, ...
... Researchers have developed an improved coating technique that could ... patients, own bone. The stronger connection -- created by ... growth -- could allow the implants to last longer. ... engineered protein that mimics the body,s own cell-adhesion material ...
Cached Biology Technology:Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 2US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 3US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research 4Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 2Titanium coating with protein 'flower bouquet' nanoclusters strengthens implant attachment 3
(Date:11/15/2014)... Nov. 13, 2014  While we may still be a ... used in "Star Trek" to gain instant access to all ... work with smartphones and tablets for monitoring and measuring our ... world. This may seem a tad Orwellian to some, but ... some of these technological opportunities into their healthcare regime. ...
(Date:11/7/2014)... by Dr. Debra Auguste, associate professor, biomedical engineering, ... City College of New York, have identified a ... one of the most aggressive forms of breast ... a high mortality rate owing to aggressive proliferation ... options. However, Professor Auguste,s team, discovered the overexpression ...
(Date:11/6/2014)... because of metastasis, yet progress in preventing and ... "It,s been particularly challenging to design drugs that ... in systems biology at Harvard Medical School. ... they,ve already metastasized." , Gujral and colleagues have ... researchers better understand how metastasis begins. Their findings ...
Breaking Biology News(10 mins):Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Migration negation 2Migration negation 3
... in the open ocean may force scientists to rethink ... ocean ecosystems. A research team led by Jonathan Zehr, ... Santa Cruz, characterized the new microbe by analyzing its ... to grow it in the laboratory. Zehr ...
... professor at The University of Texas at Austin, will ... on Greenhouse Gas Control Technologies that examines a unique ... of CO2 escaping via buoyancy. When: Nov. 19, ... 2500 Calvert St. NW, in Washington, D.C. The research ...
... University Biologist Richard Bonneau has been named one of ... Discover magazine. Bonneau, 33, is an assistant ... and Systems Biology and the university,s Courant Institute of ... appears in Discover,s December issue. Bonneau,s ...
Cached Biology News:Mysterious microbe may play important role in ocean ecology 2Mysterious microbe may play important role in ocean ecology 3Engineer to present leak-proof method for carbon dioxide storage at international conference 2NYU biologist Bonneau named among 20 "visionary" scientists under 40 by Discover magazine 2
...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
...
Biology Products: